Association between elevated liver enzymes and C-reactive protein - Possible hepatic contribution to systemic inflammation in the metabolic syndrome

被引:205
作者
Kerner, A
Avizohar, O
Sella, R
Bartha, P
Zinder, O
Markiewicz, W
Levy, Y
Brook, GJ
Aronson, D
机构
[1] Rambam Med Ctr, Dept Cardiol, IL-31096 Haifa, Israel
[2] Rambam Med Ctr, Ctr Prevent Med, IL-31096 Haifa, Israel
[3] Rambam Med Ctr, Dept Internal Med D, IL-31096 Haifa, Israel
[4] Rambam Med Ctr, Dept Lab Med, IL-31096 Haifa, Israel
[5] Rappaport Fac Med, Haifa, Israel
关键词
C-reactive protein; inflammation; liver steatosis; metabolic syndrome; nonalcoholic fatty liver; obesity;
D O I
10.1161/01.ATV.0000148324.63685.6a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - The objective of this study was to test whether the frequent association between liver enzyme elevations and various components of the metabolic syndrome is associated with higher C-reactive protein (CRP) levels. Methods and Results - Alanine aminotransferase (ALT), alkaline phosphatase (Alk-P), and high-sensitivity CRP were measured in 1740 subjects. Adjusted geometric mean CRP was calculated for subjects with normal and elevated ALT and for subjects with normal and elevated Alk- P, adjusting for age, sex, smoking, physical activity, body mass index, fasting glucose, triglycerides, the presence of hypertension and low HDL cholesterol, and use of aspirin or hormone replacement therapy. Adjusted CRP levels were higher in subjects with elevated ALT (2.21 versus 1.94 mg/L, P=0.028) or elevated Alk-P (2.58 versus 1.66 mg/L, P<0.0001). Logistic regression showed that compared with subjects with normal liver function tests, the adjusted odds for high-risk CRP (>3 mg/L) were significantly higher in subjects with elevated ALT (OR, 1.5; 95% CI, 1.2 to 1.9, P=0.002) or elevated Alk-P (OR, 2.1; 95% CI, 1.7 to 2.6, P<0.0001). Conclusions - Elevations of liver enzymes are associated with higher CRP concentrations. Hepatic inflammation secondary to liver steatosis is a potential contributor to the low-grade inflammation associated with the metabolic syndrome.
引用
收藏
页码:193 / 197
页数:5
相关论文
共 42 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [4] Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome
    Aronson, D
    Bartha, P
    Zinder, O
    Kerner, A
    Markiewicz, W
    Avizohar, O
    Brook, GJ
    Levy, Y
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (05) : 674 - 679
  • [5] Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome
    Cheal, KL
    Abbasi, F
    Lamendola, C
    McLaughlin, T
    Reaven, GM
    Ford, ES
    [J]. DIABETES, 2004, 53 (05) : 1195 - 1200
  • [6] NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
    Chitturi, S
    Abeygunasekera, S
    Farrell, GC
    Holmes-Walker, J
    Hui, JM
    Fung, C
    Karim, R
    Lin, R
    Samarasinghe, D
    Liddle, C
    Weltman, M
    George, J
    [J]. HEPATOLOGY, 2002, 35 (02) : 373 - 379
  • [7] Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
  • [8] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [9] Hepatic steatosis: Innocent bystander or guilty party?
    Day, CP
    James, OFW
    [J]. HEPATOLOGY, 1998, 27 (06) : 1463 - 1466
  • [10] Nonalcoholic Steatosis and Steatohepatitis - IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines
    Diehl, AM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2002, 282 (01): : G1 - G5